Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare

Abstract

Many top-selling Medicare drugs received low added benefit ratings by the national HTA organizations of Canada, France, and Germany. When negotiating prices for these drugs, Medicare should ensure they are not priced higher than reasonable therapeutic alternatives.